

ایمان

ایمان

تغذیه درمانی پزشکی در کبد چرب


دکتر مهدیه گل زرنند

استادیار مرکز تحقیقات تغذیه در بیماری های غدد درون ریز



دانشگاه علوم پزشکی شهیدبهشتی



Healthy liver



Fatty liver



Most common concurrent diseases

Alcoholic fatty liver disease (AFLD)


Drug-induced fatty liver disease

HCV-associated fatty liver disease

Others

- Haemochromatosis
- Autoimmune hepatitis
- Celiac disease
- Wilson disease
- A/hypo-betalipoproteinaemia lipopatrophy
- Hypopituitarism, hypothyroidism
- Starvation, parenteral nutrition
- Inborn errors of metabolism
 - Wolman disease (lysosomal acid lipase deficiency)

Definitions of NAFLD, NAFL and NASH



NAFLD prevalence:

- ▶ 25-30% of adults
- ▶ 15% of children
- ▶ 50% of individuals with overweight, obesity, or diabetes

NASH prevalence:

- ▶ 5% of adults
- ▶ 20% of individuals with obesity

Pathogenesis: lifestyle and genes

▶ **Genes:**

1- PNPLA3 I148M

2- TM6SF2 E167K

▶ Associated with risk of NASH

Genotyping is not recommended routinely

► **Unhealthy lifestyles including:**

- 1- High calorie intake
- 2- Excess (saturated) fat
- 3- High fructose intake
- 4- Sedentary behaviour



Unhealthy lifestyles → **development and progression of NAFLD**

Other risk factors

- ▶ Obesity especially abdominal obesity
- ▶ Type 2 diabetes
- ▶ Hyperlipidemia
- ▶ Metabolic syndrome
- ▶ Older people > 50 years
- ▶ Smoking
- ▶ Gut microbiota

Diagnosis: protocol for evaluation of NAFLD

- ▶ Usually asymptomatic; majority discovered by chance
- ▶ Fatigue frequently present
- ▶ Right upper quadrant discomfort
- ▶ Abnormal LFTs

- ▶ ALT / AST not sensitive tool for diagnosis NAFLD/NASH

- ▶ **Ultrasound essential**
- ▶ Identify steatosis
- ▶ Cannot distinguish type of NAFLD

**To establish the degree of inflammation and fibrosis
non-invasive tools is warranted**

► **Non-invasive tools:**

1- Hepatic fibrosis markers: Fibrosis Score (NFS) and Fibrosis 4 (FIB-4)

$$\text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelet Count (10}^9\text{/L)} \times \sqrt{\text{ALT (U/L)}}}$$

NAFLD fibrosis score Online calculator

Angulo P, Hui JM, Marchesini G et al. **The NAFLD fibrosis score**
A noninvasive system that identifies liver fibrosis in patients with NAFLD
Hepatology 2007;45(4):846-854 [doi:10.1002/hep.21496](https://doi.org/10.1002/hep.21496)

Age (years)

BMI (kg/m²)

IGF/diabetes

AST

ALT

Platelets (x10⁹/l)

Albumin (g/l)

BMI: body mass index
IGF: impaired [fasting glucose](#)

2- Imaging including: Fibroscan

Advantage:

High performance for fibrosis and cirrhosis

▶ **Limitations:**


▶ Morbid obesity

▶ Ascites

▶ Extra-hepatic cholestasis

▶ Pregnancy

Cirrhosis Prevention in NAFLD



Abbreviations: ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, cT1 = Liver multiscan, CVD = Cardiovascular disease, ELF = Enhanced liver fibrosis test™, FIB-4 = Fibrosis-4 index, kPa = Kilopascals, LSM = Liver stiffness measurement, MRE = Magnetic resonance elastography, T2D = Type 2 diabetes mellitus

COPYRIGHT © 2022 AACE | MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE. <https://doi.org/10.1016/j.jeprec.2022.03.010>

Algorithm Figure 2

Liver Biopsy: Gold Standard for fibrosis

- ▶ Sampling errors
- ▶ Expensive
- ▶ Need hospitalization
- ▶ Dependent of observers interpretation

Treatment: diet and lifestyle changes



Aims:



- ▶ Improvement of liver histology including regression of fibrosis or resolution of NASH
- ▶ Changes in quantitative parameters assessing liver fat content
- ▶ Changes in quantitative assessment of liver fibrosis
- ▶ Changes in transaminases (ALT/AST) as a surrogate for hepatic inflammation
- ▶ Changes in metabolic parameters

Recommendations

- ▶ Healthy diet and habitual physical activity
- ▶ No pharmacotherapy

	EASL-EASD-EASO 2016 ⁸	AASLD 2018 ⁹	ESPEN 2019 ¹⁰	APASL 2020 ¹¹
Energy restriction	500-1000 kcal energy deficit/day to induce a weight loss of 500-1000 g/week	Decrease caloric intake by at least 30% or by approximately 750-1000 kcal/day	Hypocaloric diet	Hypocaloric diet (500-1000 kcal deficit/day).
Weight loss	7%-10% total weight loss target	≥5% for steatosis improvement, ≥7% for histological improvement	7%-10% in overweight/obese patients >10% to improve fibrosis	7%-10% weight loss, gradual weight loss (up to 1 kg/week)
Macronutrient composition	<ul style="list-style-type: none"> • Low-to-moderate fat and moderate-to-high carbohydrate intake • Low-carbohydrate ketogenic diets or high-protein 	NS	<ul style="list-style-type: none"> • Irrespective of macronutrient composition • Mediterranean diet to improve steatosis and insulin sensitivity 	<ul style="list-style-type: none"> • No strong evidence to support a particular dietary approach. • Plans should encourage low-carbohydrate, low-fat and Mediterranean-type diets
Fructose	Avoid fructose-containing beverages and foods	NS	NS	Exclusion of beverages high in added fructose
Alcohol	<ul style="list-style-type: none"> • Strictly keep alcohol below the risk threshold (30 g, men; 20 g, women) • Moderate alcohol intake (namely, wine) below the risk threshold is associated with lower prevalence of NAFLD, NASH and even lower fibrosis 	<ul style="list-style-type: none"> • Should not consume heavy amounts of alcohol. • Insufficient data on nonheavy consumption of alcohol 	Abstain	<ul style="list-style-type: none"> • The "cut-off" values of alcohol intake in MAFLD should be set lower than the apparent "threshold levels". • Patients with MAFLD should be advised to avoid alcohol and if that is not possible, to consume the lowest amount possible.
Coffee	No liver-related limitations.	NS	More likely to benefit health than harm	NS
Physical activity	<ul style="list-style-type: none"> • 150-200 min/week of moderate intensity aerobic physical activities in 3-5 sessions are generally preferred (brisk walking, stationery cycling) • Resistance training is also effective and promotes musculoskeletal fitness, with effects on metabolic risk factors • High rates of inactivity-promoting fatigue and daytime sleepiness reduce compliance with exercise 	<ul style="list-style-type: none"> • Physical activity more than 150 minutes/week • Moderate intensity exercise 	Increase physical activity	<ul style="list-style-type: none"> • Aerobic exercise and resistance training effectively should be tailored based on patient preferences to ensure long-term adherence. • Resistance exercise may be more feasible than aerobic exercise for patients with poor fitness.

Results of a meta-analysis:

- ▶ $WL \geq 5\%$  hepatic steatosis
- ▶ $WL \geq 7\%$  improvement in the NAFLD Activity Score (NAS)

- ▶ **Results of a recent study: $WL > 10\%$**
- ▶ 45% regression of fibrosis
- ▶ 90% resolution of steatohepatitis
- ▶ 100% improvements in NAS

Weight loss

- ▶ **EASL 2016:** 7%-10% total WL
- ▶ **AASLD 2018:** $\geq 5\%$ for steatosis improvement, $\geq 7\%$ for histological improvement
- ▶ **ESPEN 2019:** 7%-10% in overweight/obese patients, $>10\%$ to improve fibrosis
- ▶ **APASL 2020:** 7%-10% total WL

- ▶ Weight reduction not exceed approximately 1.6 kg/week

- ▶ Every 1 kg of weight lost was associated with:
- ▶ A 0.83-unit reduction in ALT
- ▶ A 0.56-unit reduction in AST
- ▶ A 0.77% point reduction in steatosis
- ▶ Limited evidence of a dose-response relationship with fibrosis or NAFLD activity score.

Energy restriction

- ▶ **EASL 2016:** 500-1000 kcal/day
- ▶ **AASLD 2018:** 750-1000 kcal/day
- ▶ **ESPEN 2019:** Hypocaloric diet
- ▶ **APASL 2020:** 500-1000 kcal/day

Macronutrient composition

- ▶ **EASL 2016:** low-carbohydrate ketogenic diets or high-protein
- ▶ **AASLD 2018:** NS
- ▶ **ESPEN 2019:** Mediterranean diet
- ▶ **APASL 2020:** low-carbohydrate, low-fat and Mediterranean-type diets

- ▶ **Low-carbohydrate diet (LCD):** reduction in intrahepatic lipid content
- ▶ Hypocaloric LCD is more effective than hypocaloric LFD
- ▶ **VLCD contains 5-10% carbohydrate:** very effective in short-term

- ▶ **Intermittent calorie restriction:** reduced LFTs but long-term

feasibility and safety is controversial

High protein diet → decrease intrahepatic lipid content

▶ animal protein or plant protein???

▶ Animal proteins → increase Met, Hcy and Cys

▶ Plant proteins → increase BCAAs

▶ **Controversy ???**


▶ **The Mediterranean diet**

▶ Fruit and vegetables

▶ Whole grains

▶ Nuts and legumes

▶ Fish and olive oil



▶ Reduces hepatosteatosis and liver stiffness measurement (LSM)

▶ Reduced risk of HCC or liver-related death

▶ A systematic review and meta-analysis of 13 interventions reduced:


✓ ALT (-6.59)

✓ Fatty Liver Index (FLI) (-15.6)


✓ Liver stiffness (-0.75)

✓ No effect on AST and hepatic steatosis

Processed food and Fructose

- ▶ **EASL 2016:** Avoid processed foods and fructose-containing beverage and foods
- ▶ **AASLD 2018:** NS
- ▶ **ESPEN 2019:** NS
- ▶ **APASL 2020:** Exclusion of processed foods and beverages high in added fructose
- ▶ Based on a meta-analysis, total fructose-containing sugars  increased intrahepatocellular lipid (IHCL) by % 10

- ▶ **SSB** → higher NAFLD prevalence, NASH presence and fibrosis
- ▶ **Fructose-** but not **glucose-SSB** have been associated with:
 - ▶ increased *de novo* lipogenesis
 - ▶ dyslipidemia
 - ▶ visceral adiposity
 - ▶ impaired insulin sensitivity
- ▶ SSBs providing 27% to 30% excess energy led to a moderate increased IHCL by 10% and ALT by 11%



Alcohol

- ▶ **EASL 2016:** <30 g for men and 20 g for women
- ▶ **AASLD 2018:** Not consume heavy amounts of alcohol
- ▶ **ESPEN 2019:** Abstain
- ▶ **APASL 2020:** Lower than “threshold levels” in MAFLD should be set

Coffee

- ▶ **EASL 2016:** No limitations
- ▶ **AASLD 2018:** NS
- ▶ **ESPEN 2019:** Benefit health more than harm
- ▶ **APASL 2020:** NS

Based on some studies:

- ▶ Increasing antioxidant capacity
- ▶ Suppressing inflammation
- ▶ Decreasing hepatic lipid accumulation
- ▶ Regulating gut Microbiota
- ▶ Improving NAFLD

▶ Results of a meta-analysis of 11 epidemiological studies indicated regular coffee consumption leads to:

- ✓ A 23% lower risk of NAFLD incident
- ✓ A 33% lower risk of liver fibrosis in NAFLD patients

Although there are some controversy

Exercise

- ▶ **EASL 2016:** 150-200 min/wk of moderate intensity aerobic PA (3-5 sessions)
and resistance training is also effective
- ▶ **AASLD 2018:** > 150 min/wk moderate intensity PA
- ▶ **ESPEN 2019:** Increase physical activity
- ▶ **APASL 2020:** Aerobic exercise and resistance training


▶ Result of a meta-analysis including 24 studies (18 RCTs and six non-RCTs, encompassing 1014 patients with NAFLD) indicated:

✓ Moderate-intensity continuous training → decrease of liver enzymes and liver fat

✓ High-intensity interval training → decrease of liver fat

- ▶ Meta-analysis on 10 studies (316 individuals who had NAFLD) has shown:
- ▶ Exercise without significant weight loss significantly reduced the intrahepatic lipid (IHL) content and ALT, AST.
- ▶ Aerobic exercise alone significantly reduced IHL, ALT, and AST.
- ▶ Resistance training alone significantly reduced TC and TG.
- ▶ A combination of both exercise types significantly reduced IHL.

Treatment: pharmacotherapy



- ▶ Treatment should be indicated in:
 - ▶ Progressive NASH
 - ▶ Early-stage NASH with risk of fibrosis progression*
 - ▶ Active NASH with high necro-inflammatory activity

No drugs are approved for NASH

No specific therapy can be recommended

Any drug treatment is off label

Vitamin E (800 IU/d)

- ▶ Improve steatosis, inflammation and ballooning
- ▶ (histological improvement ≥ 2 point reduction in NAS)
- ▶ Resolution of NASH
- ▶ Concerns about long-term safety exist
 - * incidence of prostate cancer and
 - * hemorrhagic stroke
- ▶ **The optimal duration of therapy is unknown → up 6 months**

Pioglitazone (PPAR γ agonist)

- ▶ Improved all histological features
- ▶ Achieved resolution of NASH more often
- ▶ **A meta-analysis of eight RCTs found pioglitazone is efficacious for:**
- ▶ NASH resolution (OR: 3.22)
- ▶ Improvement of advanced fibrosis (OR: 3.15)
- ▶ Reversal of fibrosis (OR: 1.66)

Two new drugs:

1- Sodium glucose co-transporter 2 (SGLT2) inhibitor

- ▶ *Dapagliflozin*
- ▶ *Empagliflozin*

2- GLP-1 analogue

- ▶ *Liraglutide*
- ▶ *Semaglutide*

Synbiotics and probiotics:

- ▶ Improving insulin resistance
- ▶ Improving hepatic steatosis
- ▶ Decreased hepatic enzymes
- ▶ Reducing NAFLD progression
- ▶ No beneficial effects on fibrosis
- *Probiotics marginally are effective*

- ▶ Results are inconsistent.
- ▶ Effective strains: Bifidobacteria, Lactobacili, S.thermophiles
- ▶ **Safe & well tolerated**

Co-administration of prebiotics:

- ▶ Improving lipid profile
- ▶ Improving Insulin resistance
- ▶ Improving liver enzymes
- ▶ Improving hepatosteatosis
- ▶ **Prebiotics alone showed no effectiveness**

Omega 3:

- ▶ Reduced circulating TG levels (2 g/day)
- ▶ Reduced inflammatory markers
- ▶ Reduced AST & ALT

- ▶ **Safe up to 4 g/d & tolerated (occasional abdominal discomfort)**
- ▶ may atrial fibrillation???

Possible Interaction:


- ▶ Anticoagulant and antiplatelet drugs, herbs and supplements
- ▶ Blood pressure drugs, herbs and supplements
- ▶ Contraceptive drugs
- ▶ Orlistat
- ▶ Vitamin E

Vitamin D3:

- ▶ Improving of insulin sensitivity
- ▶ Reducing production of inflammatory markers
- ▶ Reducing hepatic inflammation
- ▶ Inhibiting of liver fibrosis

- ▶ **Safe and well tolerated**

Herbal Medicine



Silymarin:

- ▶ Improving hepatostatosis and fatty liver enzymes
- ▶ Improving insulin resistance
- ▶ Improving glucose and lipid metabolism
- ▶ In NASH, improves fibrosis and liver stiffness
- ▶ In cirrhosis, reduced mortality (420 mg/d)
- ▶ **Safe (short-term) & well tolerated**

Interaction:

- ▶ Diazepam
- ▶ Warfarin
- ▶ Diabetes medications
- ▶ Raloxifene
- ▶ Simeprevir
- ▶ Sirolimus

Resveratrol:

- ▶ Improving most of inflammatory indices
- ▶ Improving liver enzymes
- ▶ Reducing hepatic steatosis
- ▶ Improving liver damages

- ▶ **Safe & well tolerated up to 1 g/d (no > 2.5 g/d)**

Curcumin:

- ▶ Improved inflammation and metabolic markers
- ▶ Improved gut microbiota
- ▶ Reducing liver enzymes
- ▶ Improving NAFLD (> 1000 mg/d)
- ▶ Maybe mitigating NASH progression

- ▶ **Safe & well tolerated but maybe low adherence**

Possible Interaction:

- ▶ Anticoagulant / Antiplatelet drugs
- ▶ Diabetes medications
- ▶ Antitumor drugs
- ▶ Hepatotoxic drugs (methotrexate)

Berberine:

- ▶ Improved oxidative stress and inflammatory markers
- ▶ Improved glucose, lipid profile, and insulin resistance
- ▶ Reducing liver fat content

- ▶ **Safe & well tolerated up to 1 g/d**




Image of Fig.1

Treatment: surgery

Bariatric surgery:

- ▶ Reduces liver fat and is likely to reduce NASH progression
- ▶ **Prospective data have shown an improvement in all histological lesions of NASH, including fibrosis**

- ▶ **A meta-analysis of 32 studies:**
- ▶ Resolution of steatosis in 66%
- ▶ Fibrosis in 40% of patients
- ▶ **Worsened in 12% of these patients**

Liver transplantation:

- ▶ An accepted procedure in patients with NASH and end-stage liver disease. Overall survival is comparable to other indications, despite a higher cardiovascular mortality.
- ▶ **Only for patients with NASH and liver failure and/or HCC**



Thank you for your
time.

Any questions?

